Compare Tesla, Inc. (TSLA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Tesla, Inc. trades at $327.53 (market cap $1.31T), while State Street SPDR S&P Biotech ETF trades at $159.42. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| TSLA | XBI | |
|---|---|---|
Market Cap | $1.31T | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $489.88 | $164.28 |
52-Week Low | $298.16 | $86.92 |
Enterprise Value | $1.29T | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $326.95, down 1.18% on the day, amid a bearish technical signal and mixed fundamentals. The stock faces pressure from a recent earnings miss in Q2 2026 but maintains strong operating cash flow of $14.75B in 2025. Recent news highlights regulatory approval for its driver-assistance software in Europe (Reuters, 2026-04-10) and a surge in German registrations, though competition and valuation concerns persist.
Outlook remains bifurcated: long-term growth hinges on AI and autonomy execution, but near-term risks include high P/E of 308.16 and softening auto demand. Analyst consensus price target of $393.87 suggests upside potential if innovation milestones are met, yet investor patience is required amid volatility.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
